Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onabotulinum toxin A versus extended-release tolterodine in idiopathic overactive bladder in children
2014-001068-36Phase 3Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Sep 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A, tolterodine in overactive bladder (OAB), sponsored by Manchester University NHS Foundation Trust. Started Sep 2014; status: completed.
02
Drugs
botulinum toxin type Atolterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2014-001068-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001068-36.